PE20230112A1 - Formulaciones de anticuerpos anti-tslp humanos y metodos de tratamiento de una enfermedad inflamatoria - Google Patents
Formulaciones de anticuerpos anti-tslp humanos y metodos de tratamiento de una enfermedad inflamatoriaInfo
- Publication number
- PE20230112A1 PE20230112A1 PE2022001741A PE2022001741A PE20230112A1 PE 20230112 A1 PE20230112 A1 PE 20230112A1 PE 2022001741 A PE2022001741 A PE 2022001741A PE 2022001741 A PE2022001741 A PE 2022001741A PE 20230112 A1 PE20230112 A1 PE 20230112A1
- Authority
- PE
- Peru
- Prior art keywords
- methods
- inflammatory disease
- tslp antibody
- treatment
- human anti
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
En la presente se proporcionan composiciones acuosas que comprenden (a) un anticuerpo anti-TSLP a una concentracion mayor que aproximadamente 140 mg/ml, (b) un tensioactivo y (c) al menos un aminoacido basico o una sal del mismo. Tambien se proporcionan composiciones acuosas que comprenden composiciones acuosas que comprenden (a) un anticuerpo anti-TSLP a una concentracion mayor que aproximadamente 140 mg/ml, (b) un tensioactivo y (c) al menos una sal de calcio o sal de magnesio. Tambien se proporcionan articulos de fabricacion relacionados, jeringas precargadas y viales que comprenden las composiciones de la presente divulgacion. Se proporcionan en la presente usos de las composiciones para tratar una enfermedad inflamatoria, por ejemplo, la dermatitis atopica. Ademas, se proporcionan en la presente metodos de preparacion de un anticuerpo estable y liquido que tiene una viscosidad de menos de aproximadamente 100 cP.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062976007P | 2020-02-13 | 2020-02-13 | |
| US202163148105P | 2021-02-10 | 2021-02-10 | |
| PCT/US2021/017880 WO2021163504A1 (en) | 2020-02-13 | 2021-02-12 | Formulations of human anti-tslp antibodies and methods of treating inflammatory disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20230112A1 true PE20230112A1 (es) | 2023-01-27 |
Family
ID=74858823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022001741A PE20230112A1 (es) | 2020-02-13 | 2021-02-12 | Formulaciones de anticuerpos anti-tslp humanos y metodos de tratamiento de una enfermedad inflamatoria |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20230078678A1 (es) |
| EP (1) | EP4103235A1 (es) |
| JP (1) | JP2023513312A (es) |
| KR (1) | KR20220140772A (es) |
| CN (1) | CN115279404A (es) |
| AU (1) | AU2021219839A1 (es) |
| BR (1) | BR112022016010A2 (es) |
| CA (1) | CA3166964A1 (es) |
| CL (1) | CL2022002193A1 (es) |
| CO (1) | CO2022012868A2 (es) |
| CR (1) | CR20220457A (es) |
| IL (1) | IL295042A (es) |
| JO (1) | JOP20220183A1 (es) |
| MX (1) | MX2022010012A (es) |
| PE (1) | PE20230112A1 (es) |
| UY (1) | UY39083A (es) |
| WO (1) | WO2021163504A1 (es) |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP0814159B1 (en) | 1990-08-29 | 2005-07-27 | GenPharm International, Inc. | Transgenic mice capable of producing heterologous antibodies |
| US7982016B2 (en) | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
| US8359965B2 (en) | 2007-09-17 | 2013-01-29 | Oxford J Craig | Apparatus and method for broad spectrum radiation attenuation |
| TW201018482A (en) | 2008-08-08 | 2010-05-16 | Glaxo Wellcome Mfg Pte Ltd | Novel treatment |
| BR112012010707B1 (pt) | 2009-11-04 | 2022-08-30 | Merck Sharp & Dohme Corp | Anticorpo ou fragmento de ligação ao antígeno do mesmo, composição, e, uso do anticorpo ou fragmento de ligação ao antígeno do mesmo |
| WO2012007495A1 (en) | 2010-07-15 | 2012-01-19 | F. Hoffmann-La Roche Ag | Antibodies specifically binding to human tslpr and methods of use |
| AT510032B1 (de) | 2010-11-30 | 2012-01-15 | Steiner Erwin Ing | Montageeinrichtung für fassadenelemente |
| US9100245B1 (en) | 2012-02-08 | 2015-08-04 | Amazon Technologies, Inc. | Identifying protected media files |
| US20140227250A1 (en) * | 2012-08-23 | 2014-08-14 | Merck Sharp & Dohme Corp. | Stable formulations of antibodies to tslp |
| US9306926B2 (en) | 2013-03-15 | 2016-04-05 | Brian A. Truong | User authentication using unique hidden identifiers |
| AR103891A1 (es) | 2015-03-11 | 2017-06-14 | Glaxosmithkline Ip Dev Ltd | Proteínas de unión a tslp, ácido nucleico aislado que la codifica, vector y célula hospedadora que lo comprenden, método para producir dicha proteína, su uso para fabricar un medicamento, composición farmacéutica y kit que la comprenden |
| UY36889A (es) | 2015-09-09 | 2017-04-28 | Novartis Ag | Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas |
| TWI787161B (zh) * | 2015-12-18 | 2022-12-21 | 日商安斯泰來製藥股份有限公司 | 含有抗人類ｔｓｌｐ受體抗體之醫藥組成物 |
| JOP20190243A1 (ar) * | 2017-04-12 | 2019-10-13 | Medimmune Llc | علاج الربو بجسم مضاد لـ tslp |
| JP7200134B2 (ja) | 2017-06-08 | 2023-01-06 | アムジエン・インコーポレーテツド | トルク駆動式薬物送達デバイス |
| MA50557A (fr) | 2017-11-10 | 2020-09-16 | Amgen Inc | Pistons pour dispositifs d'administration de médicament |
| MA52013A (fr) | 2018-03-13 | 2021-01-20 | Amgen Inc | Procédés de préparation de polypeptides résistant à la trypsine pour analyse par spectrométrie de masse |
| CA3109988A1 (en) | 2018-10-15 | 2020-04-23 | Amgen Inc. | Platform assembly process for drug delivery device |
| KR20210076935A (ko) | 2018-10-15 | 2021-06-24 | 암젠 인크 | 댐핑 메커니즘을 갖는 약물 전달 장치 |
-
2021
- 2021-02-12 PE PE2022001741A patent/PE20230112A1/es unknown
- 2021-02-12 CN CN202180017163.9A patent/CN115279404A/zh active Pending
- 2021-02-12 IL IL295042A patent/IL295042A/en unknown
- 2021-02-12 AU AU2021219839A patent/AU2021219839A1/en active Pending
- 2021-02-12 US US17/760,427 patent/US20230078678A1/en active Pending
- 2021-02-12 BR BR112022016010A patent/BR112022016010A2/pt unknown
- 2021-02-12 CA CA3166964A patent/CA3166964A1/en active Pending
- 2021-02-12 MX MX2022010012A patent/MX2022010012A/es unknown
- 2021-02-12 KR KR1020227030979A patent/KR20220140772A/ko unknown
- 2021-02-12 WO PCT/US2021/017880 patent/WO2021163504A1/en active Application Filing
- 2021-02-12 JO JOP/2022/0183A patent/JOP20220183A1/ar unknown
- 2021-02-12 JP JP2022548653A patent/JP2023513312A/ja active Pending
- 2021-02-12 CR CR20220457A patent/CR20220457A/es unknown
- 2021-02-12 EP EP21710162.5A patent/EP4103235A1/en active Pending
- 2021-02-12 UY UY0001039083A patent/UY39083A/es unknown
-
2022
- 2022-08-12 CL CL2022002193A patent/CL2022002193A1/es unknown
- 2022-09-09 CO CONC2022/0012868A patent/CO2022012868A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2022010012A (es) | 2022-09-07 |
| CR20220457A (es) | 2023-01-09 |
| IL295042A (en) | 2022-09-01 |
| AU2021219839A1 (en) | 2022-08-25 |
| US20230078678A1 (en) | 2023-03-16 |
| UY39083A (es) | 2021-08-31 |
| WO2021163504A1 (en) | 2021-08-19 |
| BR112022016010A2 (pt) | 2022-12-20 |
| CN115279404A (zh) | 2022-11-01 |
| JOP20220183A1 (ar) | 2023-01-30 |
| CO2022012868A2 (es) | 2022-12-09 |
| JP2023513312A (ja) | 2023-03-30 |
| KR20220140772A (ko) | 2022-10-18 |
| CL2022002193A1 (es) | 2023-03-24 |
| EP4103235A1 (en) | 2022-12-21 |
| CA3166964A1 (en) | 2021-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR105712A1 (es) | Composiciones de insulina de rápida acción | |
| ECSP17034829A (es) | Formulación estable de proteina en solucion que contiene una alta concentracion de un anticuerpo anti-vegf | |
| BR112012022223A8 (pt) | Formulação de proteína concentrada, uso e método de preparação da mesma | |
| BR112013018920A2 (pt) | composições de nanopartículas, formulações destas e seus usos | |
| BR112015022210A2 (pt) | formulações farmacêuticas aquosas estáveis, seu uso, artigo de manufatura, métodos de redução da agregação de um anticorpo monoclonal terapêutico e método de produção de uma formulação farmacêutica. | |
| AR109494A1 (es) | Formulaciones de anticuerpos inhibidores de masp-2 de baja viscosidad y altamente concentradas, kits, y métodos | |
| AR076607A1 (es) | Composicion acuosa. metodo para producir una preparacion altamente concentrada de inmunoglobulina de uso subcutaneo | |
| BR112013027674A2 (pt) | "usos de composições de nanopartículas, composições compreendendo as referidas nanopartículas e cateter com uma agulha". | |
| AR048439A1 (es) | Composiciones farmaceuticas y metodos para tratar la infeccion por vih | |
| CL2021000207A1 (es) | Nuevas proteínas de fusión específicas para cd137 y pd-l1 | |
| JP2021169477A (ja) | 眼科用組成物 | |
| CL2021002107A1 (es) | Triamtereno o nolatrexed para uso en el tratamiento de fenilcetonuria. | |
| WO2017131130A1 (ja) | コンドロイチン硫酸及びヒアルロン酸を含有する安定化された水性組成物 | |
| WO2022192594A3 (en) | Nucleic acid molecules and vaccines comprising same for the prevention and treatment of coronavirus infections and disease | |
| PE20230112A1 (es) | Formulaciones de anticuerpos anti-tslp humanos y metodos de tratamiento de una enfermedad inflamatoria | |
| ECSP21043639A (es) | Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf | |
| AR121329A1 (es) | Formulaciones de anticuerpos anti-tslp humanos y métodos de tratamiento de una enfermedad inflamatoria | |
| AR039895A1 (es) | Composicion que comprende una vitamina, una sal de metal y una insulina o una hormona del crecimiento y uso de dichos componentes para prepararla | |
| CO2023002650A2 (es) | Formas farmacéuticas sólidas de palbociclib | |
| AR045258A1 (es) | Un producto farmaceutico para inyeccion | |
| BR112018071394A2 (pt) | polímero de enxerto, métodos para a preparação de um polímero de enxerto, para a preparação de um sistema de dispensação e para prevenir, tratar ou melhorar um distúrbio médico, composição, preenchedor de tecido macio, uso de um polímero de enxerto, e, kit. | |
| EA202192534A1 (ru) | Системы стабилизации и контролируемого высвобождения для лекарственных средств, нестабильных при стерилизации | |
| BR112018008769A2 (pt) | formulações farmacêuticas, formulações líquidas aquosa reconstituída e liofilizada, seringa, método de fabricação de uma formulação farmacêutica, método para tratamento de uma doença e uso de uma formulação reconstruída | |
| BR112022004836A2 (pt) | Processo para preparar um hidrogel super poroso plastificado, uso de um ou mais hidrogéis super porosos plastificados e formulação de dosagem oral | |
| RU2564951C1 (ru) | Композиция водного раствора рекомбинантного интерферона альфа-2 человека для ректального применения |